Innocare
Changping
About Innocare
InnoCare is a biopharmaceutical company rooted in China with the global vision to discover and develop novel treatment for cancer and autoimmune diseases. InnoCare' s core scientific team members have strong educational backgrounds and rich drug innovation experiences in the U.S. and China. InnoCare also has an elite Scientific Advisory Board (SAB) comprising of professionals from leading universities, hospitals, academic institutions and pharmaceutical industry. InnoCare is forging forward on the critical path of defeating diseases and pushing the boundaries of innovation into unchartered territories.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $500K – $1M
- Total funding: $215.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2021)
- Ticker: hkg:9969
- Website: innocarepharma.com
- Phone: +86 10 66609999
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/innocare-94412 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.